News
According to Evaluate Pharma, the top 5 brightest innovations from large pharmaceutical companies include Tirzepatide and Donanemab (Eli Lilly - NPV 18, 7 and $ 17.9 billion), Deukravitinib (Bristol Myers Squibb, NPV $ 9.1 billion), Tirgolumab ( Roche, NPV $ 5.8 billion) and SAR442168 (tolebrutinib) (Sanofi, NPV $ 5.5 billion).
Read about which companies and with what innovations come to these leaders "on five" at: https://bit.ly/3hRthw8